"Perospirone"

Long-term Efficacy and Tolerability of Perospirone for Young Help-seeking People at Clinical High Risk: a Preliminary Open Trial. Interest in the "at-risk mental state" (ARMS) for psychosis has increased because early intervention is expected to delay or prevent the onset of schizophrenia. However, the optimum intervention strategy remains controversial, especially with regard to antipsychotics . Although administration of antipsychotic medications is often associated with adverse effects and raises ethical considerations, recent studies have shown that some novel antipsychotics are safer and more tolerable for young people than conventional antipsychotics. We investigated whether administration of perospirone, a combined serotonin (5-HT)/dopamine antagonist and 5-HT1A receptor agonist, could

A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients. To evaluate the efficacy and safety of aripiprazole and perospirone in Japanese patients with schizophrenia. In this 12-week, randomized, flexible-dose, open-label study, patients diagnosed with schizophrenia were randomized to receive aripiprazole (3-30 mg/day, n=49 ) or perospirone (8-48 mg/day, n=51). Efficacy and safety were evaluated using the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity Scale (CGI-S), the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) and the Barnes Akathisia Rating Scale (BAS) before treatment and every 4 weeks after the initiation of treatment. Fifty-eight patients completed this study (aripiprazole, n=31

perospirone hydrochloride hydrate mosapramine hydrochloride

or nutritionalsupplements. Six pharmacological studies (40.0%) have beenpublished, two uncontrolled studies (33.3%) and four RCTs(66.7%). The mean therapy duration was 6.83 months(S.D. = 4.31, range = 2–12), the mean follow-up period was15.29 months (S.D. = 16.23, range = 2–48), and the drop-out rateranged between 13.0 and 55.0%. These trials investigated theefficacy of aripiprazole [123] and perospirone [113] using

discontinuation/dose reduction/switch of antipsychotics, tolerance to previously observed therapeutic effects, co-occurring TD, and psychotic exacerbation by life stressors. We review 3 recent studies on the prevalence rates of SP, and the link to treatment resistance and psychotic relapse in the era of second-generation antipsychotics (risperidone, paliperidone, perospirone, and long-acting injectable

, aripiprazole, asenapine, blonanserine, brexpiprazole, cariprazine, clozapine, iloperidone, lumateperone, lurasidone, olanzapine, olanzapine-samidorphan, paliperidone, perospirone, quetiapine, risperidone, sertindole, ziprasidone, zotepine. However, we will include first-generation antipsychotics (FGAs) when they were used as comparators of SGAs, as well as placebo and no treatment

the antipsychotic, antidepressant, and anxiolytic compounds that included perospirone, nefazodone, haloperidol, aripiprazole, trazodone, and buspirone. Fluoxetine and risperidone were also active at 1 μM, and another 10 compounds in this class of pharmaceuticals were identified in the screen at concentrations of 10 μM. Increased levels of 7-DHC are associated with Smith-Lemli-Opitz syndrome (SLOS), a human

efficacy and tolerability in schizophrenia, based on a randomized controlled study of antipsychotics with mechanisms involving either full antagonism or partial agonism of D2-R. Patients with schizophrenia were recruited and given perospirone or aripiprazole in a 12-week, flexible-dose, open-label, randomized controlled study. Data were analyzed after dividing the patients into antipsychotic-naïve and antipsychotic-treated group according to antipsychotic medication histories. Efficacy and safety were evaluated using the Positive and Negative Syndrome Scale (PANSS), the Drug-Induced Extrapyramidal Symptoms Scale, and the Barnes Akathisia Rating Scale. In patients receiving perospirone, the antipsychotic-naïve group (n = 22) showed greater symptom improvement than that shown by the antipsychotic-treated

receptor partial agonism in Japanese patients with schizophrenia. Perospirone or aripiprazole was administered to 100 patients with schizophrenia in a randomized controlled study. Candidate SNPs were rs6295 (which affects HTR1A expression and function), rs1364043, rs878567, and rs10042486. Efficacy at week 12 of treatment was evaluated using the Positive and Negative Syndrome Scale (PANSS) 5-factor

of second-generation antipsychotic drugs with a high affinity for this receptor in Japanese schizophrenia. Perospirone or aripiprazole was administered to 100 patients with schizophrenia in a randomized controlled study. All patients were genotyped for three candidate SNPs (rs12412496, rs7916403, and rs1935349). Patient improvement on the Positive and Negative Syndrome Scale (PANSS) total score at 12

, iloperidone, loxapine, lumateperone, lurasidone, mesoridazine, metoclopramide, molindone, olanzapine, paliperidone, penfluridol, perazine, perospirone, perphenazine, pimavanserin, pimozide, pipamperone, prochlorperazine, promazine, quetiapine, risperidone, ritanserin, sertindole, sulpiride, thioridazine, thiothixene, tiapride, trifluoperazine, trifluperidol, triflupromazine, ziprasidone, zotepine

, asenapine, blonanserin, brexpiprazole, cariprazine, carpipramine, clocapramine, clorotepine, clotiapine, clozapine, iloperidone, levosulpiride, lumateperone, lurasidone, melperone, mosapramine, nemonapride, olanzapine, paliperidone, perospirone, quetiapine, remoxipride, reserpine, risperidone, sertindole, sulpiride, sultopride, tiapride, veralipride, ziprasidone, zotepine, pimavanserin, stepholidine

Singapore that included the descriptors 'atypic* antipsychotic*', 'second-generation antipsychotic*', 'clozapine', 'risperidone', 'olanzapine', 'ziprasidone', 'quetiapine', 'sertindole', 'aripiprazole', 'paliperidone', 'amisulpride', 'zotepine', 'asenapine', 'iloperidone', 'lurasidone', 'perospirone' and 'blonanserin' in the article titles. Certain bibliometric indicators of production and dispersion (e.g

, lumateperone, lurasidone, olanzapine, olanzapine-samidorphan, paliperidone, quetiapine, risperidone, sertindole, ziprasidone, zotepine) and placebo, and the second-generation antipsychotics blonanserine and perospirone which are only available in Japan and a few other Eastern Asian countries. Moreover, we will include the first-generation antipsychotics haloperidol, chlorpromazine, perphenazine

, zotepine) and placebo, and the second-generation antipsychotics blonanserine and perospirone which are only available in Japan and a few other Eastern Asian countries. Moreover, we will include the first-generation antipsychotics haloperidol, chlorpromazine, perphenazine and sulpiride.We will include these compounds in any form of administration. In fixed-dose studies we will only include target

, risperidone, sertindole, ziprasidone, zotepine) and placebo, and the second-generation antipsychotics blonanserine and perospirone which are only available in Japan and a few other Eastern Asian countries. Moreover, we will include the first-generation antipsychotics haloperidol, chlorpromazine, perphenazine and sulpiride.We will include these compounds in any form of administration. In fixed-dose studies

Perospirone in the treatment of patients with delirium. Perospirone is a recently developed atypical antipsychotic with potent serotonin 5-HT2 and dopamine D2 antagonist activity. Other atypical antipsychotics including risperidone, quetiapine and olanzapine have been widely used for treatment, not only for schizophrenia symptoms but also for delirium, because of their low potential to induce extrapyramidal disturbances. In the present study the effectiveness and safety of perospirone in patients with delirium are described. Thirty-eight patients with DSM-IV delirium were given open-label perospirone. To evaluate the usefulness of perospirone, scores from 13 severity items of the Delirium Rating Scale-Revised-98 were assessed. Data were gathered from October 2003 to September 2004. Perospirone